MDGL Madrigal Pharmaceuticals, Inc.
$421.99
Madrigal Pharmaceuticals, Inc. (MDGL) Earnings News
Earnings press releases, previews and reviews for Madrigal Pharmaceuticals, Inc. (MDGL), newest first. Our most recent is review: Madrigal Turns Its First Profit on Rezdiffra Strength, but Slowing Growth Rates and 2027 Pricing Pressure Keep the Debate Alive.
Tuesday
November 3, 2026
10:44 AM ET
Madrigal Turns Its First Profit on Rezdiffra Strength, but Slowing Growth Rates and 2027 Pricing Pressure Keep the Debate Alive
Earnings Whispers · Review
Tuesday
November 3, 2026
7:00 AM ET
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Monday
October 26, 2026
5:16 PM ET
Madrigal Needs ResDifera Volume to Outrun Pricing and Cost Pressure as Shares Hit Lows
Earnings Whispers · Preview
Tuesday
October 20, 2026
8:00 AM ET
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
Thursday
July 30, 2026
7:00 AM ET
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Thursday
July 16, 2026
8:00 AM ET
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026